Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ENDRA Life SciencesNDRA +1.50%19 12-1 Month Momentum % is -6.04% as of Sep. 21, 2026. GuruFocus rates NDRA with a GF Score™ of 19/100. The stock has 2 warning signs investors should review. Among 210 Medical Diagnostics & Research companies, ENDRA Life Sciences ranks better than 53.81% on this metric.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-09-21), ENDRA Life Sciences's 12-1 Month Momentum % is -6.04%.
The industry rank for ENDRA Life Sciences's 12-1 Month Momentum % or its related term are showing as below:
NDRA's 12-1 Month Momentum % is ranked better than 53.81% of 210
companies
in the Medical Diagnostics & Research industry
Industry Median: -10.3
vs NDRA: -6.04
ENDRA Life Sciences (NAS:NDRA) 12-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
ENDRA Life Sciences 12-1 Month Momentum % Related Terms
NDRA vs XWEL, MBAI, ISPC: 12-1 Month Momentum % Comparison
For the Diagnostics & Research subindustry, ENDRA Life Sciences's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ENDRA Life Sciences 12-1 Month Momentum % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, ENDRA Life Sciences's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where ENDRA Life Sciences's 12-1 Month Momentum % falls into.
ENDRA Life Sciences (NAS:NDRA) 12-1 Month Momentum % Calculation
12-1 Month Momentum % is calculated as following:
12-1 Month Momentum %
=
( Price 1-month ago
/
Price 12-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ENDRA Life Sciences (NDRA) has a 12-1 Month Momentum % of -6.04% as of Sep. 21, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on ENDRA Life Sciences and its competitors. According to the industry distribution chart, ENDRA Life Sciences ranks #97 out of 210 companies in the Medical Diagnostics & Research industry, placing it in the top 46.2%.
Is ENDRA Life Sciences' 12-1 Month Momentum % too high?
ENDRA Life Sciences' current 12-1 Month Momentum % is -6.04%. Based on the distribution chart, ENDRA Life Sciences ranks #97 out of 210 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, ENDRA Life Sciences has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does ENDRA Life Sciences' 12-1 Month Momentum % compare to XWEL and MBAI?
According to the Medical Diagnostics & Research industry distribution chart, ENDRA Life Sciences ranks #97 out of 210 companies for 12-1 Month Momentum %. This puts ENDRA Life Sciences in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Medical Diagnostics & Research company?
A good 12-1 Month Momentum % depends on the Medical Diagnostics & Research industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on ENDRA Life Sciences and its competitors. ENDRA Life Sciences's current 12-1 Month Momentum % is -6.04%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ENDRA Life Sciences stock overvalued right now?
ENDRA Life Sciences (NDRA) has a current 12-1 Month Momentum % of -6.04%. The current 12-1 Month Momentum % is -6.04%. ENDRA Life Sciences' overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For ENDRA Life Sciences (NDRA), the current 12-1 Month Momentum % is -6.04% as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ENDRA Life Sciences Inc is engaged in the development of thermo-acoustic enhanced ultrasound (TAEUS) technology to improve the capabilities of clinical diagnostic ultrasound. The company's technology is used to measure tissue composition, including the assessment of fat in the liver, and is being developed for additional clinical applications such as tissue temperature monitoring.
19GF Score
Get the complete analysis for NDRA
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NDRA has been successfully added to your 
